CHADS 2 and CHA 2 DS 2 -VASc scores as bleeding risk indices for patients with atrial fibrillation: the Bleeding with Antithrombotic Therapy Study

Hypertension Research

Volumn 37, Issue 5, 2014, Pages 463-466

  Toyoda, Kazunori ^a   Yasaka, Masahiro ^b   Uchiyama, Shinichiro ^c   Iwade, Kazunori ^d   Koretsune, Yukihiro ^e   Nagata, Ken ^f   Sakamoto, Tomohiro ^g   Nagao, Takehiko ^h   Yamamoto, Masahiro ⁱ   Gotoh, Jun ^j   Takahashi, Jun C ^a   Minematsu, Kazuo ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION KYUSHU MEDICAL CENTER   (Japan)

^c TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^d NATIONAL HOSPITAL ORGANIZATION YOKOHAMA MEDICAL CENTER   (Japan)

^e OSAKA NATIONAL HOSPITAL   (Japan)

^f RESEARCH INSTITUTE FOR BRAIN AND BLOOD VESSELS AKITA   (Japan)

^g KUMAMOTO UNIVERSITY   (Japan)

^h Department of Dentistry Oral surgery   (Japan)

ⁱ Yokohama City Brain and Stroke Center   (Japan)

^j SAITAMA NATIONAL HOSPITAL   (Japan)

more..

Author keywords

anticoagulation; atrial fibrillation; intracerebral hemorrhage; stroke; warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; WARFARIN; FIBRINOLYTIC AGENT;

ADULT; AGED; ARTICLE; BLEEDING; BRAIN ISCHEMIA; CHA2DS2 VASC SCORE; CHADS2 SCORE; FEMALE; HEART ATRIUM FIBRILLATION; HIGH RISK PATIENT; HUMAN; INTERMEDIATE RISK PATIENT; INTERNATIONAL NORMALIZED RATIO; LOW RISK PATIENT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); OBSERVATIONAL STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; ATRIAL FIBRILLATION; CLINICAL TRIAL; COMPLICATION; MIDDLE AGED; MULTICENTER STUDY; RISK; STROKE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; BRAIN ISCHEMIA; FEMALE; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK; RISK ASSESSMENT; STROKE;

EID: 84899847461     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2013.150     Document Type: Article

References (14)

1. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. ESC Committee for Practice Guidelines-CPG, Document Reviewers. 2012 Focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012; 14: 1385-1413
2. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting hemorrhage: Results from the National Registry of Atrial Fibrillation (NRAF). Am Heart J 2006; 151: 713-719
3. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest 2010; 138: 1093-1100
4. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: Results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870
5. Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The Euro Heart Survey on Atrial Fibrillation. Chest 2010; 137: 263-272
6. Toyoda K, Yasaka M, Iwade K, Nagata K, Koretsune Y, Sakamoto T, Uchiyama S, Gotoh J, Nagao T, Yamamoto M, Takahashi JC, Minematsu K. Dual antithrombotic therapy increases severe bleeding events in patients with stroke and cardiovascular disease: A prospective multicenter observational study. Stroke 2008; 39: 1740-1745
7. Toyoda K, Yasaka M, Uchiyama S, Nagao T, Gotoh J, Nagata K, Koretsune Y, Sakamoto T, Iwade K, Yamamoto M, Takahashi JC, Minematsu K. Bleeding with Antithrombotic Therapy (BAT) Study Group. Blood pressure levels and bleeding events during antithrombotic therapy: The Bleeding with Antithrombotic Therapy (BAT) Study. Stroke 2010; 41: 1440-1444
8. Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: Nationwide cohort study. BMJ 2011; 342: D124
9. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): Randomised, double-blind, placebo-controlled trial. Lancet 2004; 364: 331-337
10. Healey JS, Hart RG, Pogue J, Pfeffer MA, Hohnloser SH, De Caterina R, Flaker G, Yusuf S, Connolly SJ. Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: The atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke 2008; 39: 1482-1486
11. Banerjee A, Lane DA, Torp-Pedersen C, Lip GY. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a 'real world' atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589
12. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: A systematic review and meta-Analysis. Lancet Neurol 2010; 9: 167-176
13. Hart RG, Tonarelli SB, Pearce LA. Avoiding central nervous system bleeding during antithrombotic therapy: Recent data and ideas. Stroke 2005; 36: 1588-1593
14. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: A systematic review. Hypertension 2004; 43: 18-24